ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells

Cancer Immunology, Immunotherapy

Volumn 63, Issue 5, 2014, Pages 437-448

  Bossi, Giovanna ^a   Buisson, Sandrine ^a   Oates, Joanne ^a   Jakobsen, Bent K ^a   Hassan, Namir J ^a  

^a Immunocore Limited   (United Kingdom)

Author keywords

Cancer immunotherapy; Cross dressing; Cross presentation; Dendritic cell; ImmTAC; T cell receptor

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; HLA A2 ANTIGEN; IMCGP 100; MELANOCYTE PROTEIN PMEL 17; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DEATH; CELL KILLING; CELLULAR CROSS-DRESSING; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MELANOMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CROSS-PRIMING; DENDRITIC CELLS; GP100 MELANOMA ANTIGEN; HUMANS; IMMUNOTHERAPY; MELANOMA; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84899933079     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1525-z     Document Type: Article

References (43)

1. Borghesi L, Milcarek C (2007) Innate versus adaptive immunity: a paradigm past its prime? Cancer Res 67(9):3989-3993
2. Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T (2004) The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 95(9):697-703
3. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr (1996) Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183(1):283-287
4. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R (2006) Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24(31):5060-5069
5. Spel L, Boelens J, Nierkens S, Boes M (2013) Antitumor immune responses mediated by dendritic cells: how signals derived from dying cancer cells drive antigen cross-presentation. OncoImmunology 2:e26403
6. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF (2011) Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J Exp Med 208(10):2005-2016
7. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, Schreiber RD, Murphy TL, Murphy KM (2008) Batf3 deficiency reveals a critical role for CD8α+ dendritic cells in cytotoxic T cell immunity. Science 322(5904):1097-1100
8. Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, Wu S, Vuthoori S, Ko K, Zavala F, Pamer EG, Littman DR, Lang RA (2002) In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17(2):211-220
9. Kalos M (2012) Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses. Cancer Immunol Immunother 61(1):127-135
10. Aleksic M, Liddy N, Molloy PE, Pumphrey N, Vuidepot A, Chang KM, Jakobsen BK (2012) Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol 42(12):3174-3179
11. Bridgeman JS, Sewell AK, Miles JJ, Price DA, Cole DK (2012) Structural and biophysical determinants of αβ T-cell antigen recognition. Immunology 135(1):9-18
12. Cole DK, Pumphrey NJ, Boulter JM, Sami M, Bell JI, Gostick E, Price DA, Gao GF, Sewell AK, Jakobsen BK (2007) Human TCR-binding affinity is governed by MHC class restriction. J Immunol 178(9):5727-5734
13. Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD, Dunn SM, Mahon TM, Jakobsen BK, Rosenberg SA (2008) Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 180(9):6116-6131
14. Chlewicki LK, Holler PD, Monti BC, Clutter MR, Kranz DM (2005) High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3. J Mol Biol 346(1):223-239
15. Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E, Dunn S, Liddy N, Jacob J, Jakobsen BK, Boulter JM (2005) Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 23(3):349-354
16. Boulter JM, Glick M, Todorov PT, Baston E, Sami M, Rizkallah P, Jakobsen BK (2003) Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng 16(9):707-711
17. Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, Gostick E, Sewell AK, Lissin NM, Harwood NE, Molloy PE, Li Y, Cameron BJ, Sami M, Baston EE, Todorov PT, Paston SJ, Dennis RE, Harper JV, Dunn SM, Ashfield R, Johnson A, McGrath Y, Plesa G, June CH, Kalos M, Price DA, Vuidepot A, Williams DD, Sutton DH, Jakobsen BK (2012) Monoclonal TCR-redirected tumor cell killing. Nat Med 18:980-987
18. McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujic M, Osdal T, Gjertsen BT, Baker D, Powlesland AS, Aleksic M, Vuidepot A, Morteau O, Sutton DH, June CH, Kalos M, Ashfield R, Jakobsen BK (2013) Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother 62(4):773-785
19. Adema GJ, de Boer AJ, van't Hullenaar R, Denijn M, Ruiter DJ, Vogel AM, Figdor CG (1993) Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol 143(6):1579-1585
20. Cole DK, Yuan F, Rizkallah PJ, Miles JJ, Gostick E, Price DA, Gao GF, Jakobsen BK, Sewell AK (2009) Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem 284(40):27281-27289
21. Purbhoo MA, Sutton DH, Brewer JE, Mullings RE, Hill ME, Mahon TM, Karbach J, Jager E, Cameron BJ, Lissin N, Vyas P, Chen JL, Cerundolo V, Jakobsen BK (2006) Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J Immunol 176(12):7308-7316
22. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72(11):8463-8471
23. von Euw EM, Barrio MM, Furman D, Bianchini M, Levy EM, Yee C, Li Y, Wainstok R, Mordoh J (2007) Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. J Transl Med 5:19
24. Bossi G, Gerry AB, Paston SJ, Sutton DH, Hassan NJ, Jakobsen BK (2013) Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells. OncoImmunology 2:e26840
25. Shen L, Rock KL (2006) Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr Opin Immunol 18(1):85-91
26. Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S (2013) Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 25(2):268-276
27. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, Patterson JW, Slingluff CL Jr (2012) Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 72(5):1070-1080
28. Barrio MM, Abes R, Colombo M, Pizzurro G, Boix C, Roberti MP, Gelize E, Rodriguez-Zubieta M, Mordoh J, Teillaud JL (2012) Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells. PLoS ONE 7(7):e40311
29. Mandruzzato S, Rossi E, Bernardi F, Tosello V, Macino B, Basso G, Chiarion-Sileni V, Rossi CR, Montesco C, Zanovello P (2002) Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient. J Immunol 169(7):4017-4024
30. Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, Rimoldi D, Cerottini JC, Banchereau J, Palucka AK (2000) Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 192(11):1535-1544
31. van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, van der Voort EI, Offringa R, Toes RE, Melief CJ (2004) Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol 173(11):6753-6759
32. Dudda JC, Simon JC, Martin S (2004) Dendritic cell immunization route determines CD8+ T cell trafficking to inflamed skin: role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets. J Immunol 172(2):857-863
33. Calzascia T, Masson F, Di Berardino-Besson W, Contassot E, Wilmotte R, Aurrand-Lions M, Ruegg C, Dietrich PY, Walker PR (2005) Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by cross presenting APCs. Immunity 22(2):175-184
34. McDonnell AM, Robinson BW, Currie AJ (2010) Tumor antigen cross-presentation and the dendritic cell: where it all begins? Clin Dev Immunol 2010:539519
35. Pinzon-Charry A, Maxwell T, Lopez JA (2005) Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 83(5):451-461
36. Watchmaker PB, Urban JA, Berk E, Nakamura Y, Mailliard RB, Watkins SC, van Ham SM, Kalinski P (2008) Memory CD8+ T cells protect dendritic cells from CTL killing. J Immunol 180(6):3857-3865
37. Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM (2001) Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 166(6):3717-3723
38. Harshyne LA, Zimmer MI, Watkins SC, Barratt-Boyes SM (2003) A role for class A scavenger receptor in dendritic cell nibbling from live cells. J Immunol 170(5):2302-2309
39. Saccheri F, Pozzi C, Avogadri F, Barozzi S, Faretta M, Fusi P, Rescigno M (2010) Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. Sci Transl Med 2(44):44ra57
40. Joly E, Hudrisier D (2003) What is trogocytosis and what is its purpose? Nat Immunol 4(9):815
41. Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S (2006) Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. J Immunol 177(9):6018-6024
42. Wakim LM, Bevan MJ (2011) Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection. Nature 471(7340):629-632
43. Smyth LA, Harker N, Turnbull W, El-Doueik H, Klavinskis L, Kioussis D, Lombardi G, Lechler R (2008) The relative efficiency of acquisition of MHC: peptide complexes and cross-presentation depends on dendritic cell type. J Immunol 181(5):3212-3220